Lead the way to a healthier world by putting patients at the center of everything we do

We are focused on developing innovative therapies and transforming the lives of people with serious medical conditions.

Helping people with serious medical conditions lead fulfilling lives

Building on a track record of discovery, development and commercialization of important therapies, we have a robust and growing portfolio of treatments to address serious psychiatric, neurological and respiratory conditions.

Find out how we are addressing serious psychiatric conditions

We are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives.

Discover what we're doing to investigate serious neurological conditions

We are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions.

Explore our research in serious respiratory conditions

We strive to advance the science of medicine for respiratory conditions.

Featured News

July 21, 2017

Sunovion’s Latuda® (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia

July 18, 2017

Sunovion Expands Commitment to Building Stronger Communities through Partnerships with the Red Sox Foundation, United Way of Tri-County and Bergen Volunteer Center

July 13, 2017

Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma

Our people share a passion to make a difference

Our Commitment

Supporting patient advocacy in our communities

We partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs.

Sunovion by the numbers

  • 2ndfastest-growing pharmaceutical company in the U.S.*
  • 1,700+employees worldwide
  • 20,000+employee volunteer hours in 5 years